Insights

Innovative Cell Platform bit.bio's proprietary opti-ox precision cell programming technology offers a unique solution for scalable, consistent human cell production, presenting significant opportunities for research institutions and pharmaceutical companies seeking reliable and rapid cell sources for drug discovery and regenerative medicine.

Growth and Funding With a revenue range of 10 to 25 million dollars and securing 30 million dollars in funding, bit.bio demonstrates strong growth potential and investor confidence, making it a promising partner for collaborations and sales engagements targeting expanding biotech and research markets.

Research and Clinical Pipeline The company's development of txCells and new cell visualization products like ioTracker Cells indicates ongoing innovation in cell therapies and research tools, opening opportunities to supply research labs, biotech firms, and clinical developers interested in advanced cell models.

Market Engagement Active participation in industry events like SLAS, WC13, and awards such as the Green Impact Awards reflects a company well-integrated into the research community, providing multiple touchpoints to establish relationships with potential customers and collaborators.

Sustainability Focus Recognition for green initiatives, including Platinum status in the Green Impact Awards, highlights a sustainability-driven approach that can appeal to organizations prioritizing environmental responsibility in their R&D and procurement decisions.

bit.bio Tech Stack

bit.bio uses 8 technology products and services including Canva, RSS, HubSpot Cookie Policy Banner, and more. Explore bit.bio's tech stack below.

  • Canva
    Audio, Video, Graphics
  • RSS
    Content Management System
  • HubSpot Cookie Policy Banner
    Cookie Compliance
  • Swiper
    Javascript Libraries
  • DocuSign
    Miscellaneous
  • Java
    Programming Languages
  • Hadoop
    Programming Languages
  • Greenhouse
    Recruitment Marketing

Media & News

bit.bio's Email Address Formats

bit.bio uses at least 1 format(s):
bit.bio Email FormatsExamplePercentage
First.Last@bit.bioJohn.Doe@bit.bio
66%
First@bit.bioJohn@bit.bio
26%
Last@bit.bioDoe@bit.bio
4%
FLast@bit.bioJDoe@bit.bio
4%

Frequently Asked Questions

What is bit.bio's official website and social media links?

Minus sign iconPlus sign icon
bit.bio's official website is bit.bio and has social profiles on LinkedInCrunchbase.

What is bit.bio's SIC code NAICS code?

Minus sign iconPlus sign icon
bit.bio's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does bit.bio have currently?

Minus sign iconPlus sign icon
As of December 2025, bit.bio has approximately 162 employees across 4 continents, including EuropeNorth AmericaAsia. Key team members include Chief Scientific Officer (svp): E. M.Vp Commercial: E. P.Vice President Operations: O. G.. Explore bit.bio's employee directory with LeadIQ.

What industry does bit.bio belong to?

Minus sign iconPlus sign icon
bit.bio operates in the Biotechnology Research industry.

What technology does bit.bio use?

Minus sign iconPlus sign icon
bit.bio's tech stack includes CanvaRSSHubSpot Cookie Policy BannerSwiperDocuSignJavaHadoopGreenhouse.

What is bit.bio's email format?

Minus sign iconPlus sign icon
bit.bio's email format typically follows the pattern of First.Last@bit.bio. Find more bit.bio email formats with LeadIQ.

How much funding has bit.bio raised to date?

Minus sign iconPlus sign icon
As of December 2025, bit.bio has raised $30M in funding. The last funding round occurred on Dec 16, 2024 for $30M.

When was bit.bio founded?

Minus sign iconPlus sign icon
bit.bio was founded in 2016.

bit.bio

Biotechnology ResearchEngland, United Kingdom51-200 Employees

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. 

We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines.

Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies.

To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision.

Collaboration is at the heart of bit.bio. Join us on our journey. 

For more information on bit.bio’s trademarks, visit www.bit.bio/trademarks

Section iconCompany Overview

Website
bit.bio
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
51-200

Section iconFunding & Financials

  • $30M

    bit.bio has raised a total of $30M of funding over 5 rounds. Their latest funding round was raised on Dec 16, 2024 in the amount of $30M.

  • $10M$25M

    bit.bio's revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $30M

    bit.bio has raised a total of $30M of funding over 5 rounds. Their latest funding round was raised on Dec 16, 2024 in the amount of $30M.

  • $10M$25M

    bit.bio's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.